SV Health Investors Acquires EpiVax

The acquisition strengthens EpiVax's position as a leader in immunogenicity risk assessment for pharmaceutical and biotech companies.

Apr. 2, 2026 at 7:51pm

Got story updates? Submit your updates here. ›

A high-end, photorealistic studio still-life photograph featuring a collection of polished, geometric objects representing the analytical tools and services of EpiVax, arranged elegantly on a clean, monochromatic seamless background with sharp, dramatic studio lighting and deep shadows.The acquisition of EpiVax by SV Health Investors strengthens the company's position as a leader in precision immunogenicity risk assessment for the pharmaceutical and biotech industries.Providence Today

SV Health Investors (SVHI), a healthcare and life sciences focused private investment firm, announced the acquisition of EpiVax, Inc., a leading bioanalytical CRO specializing in immunogenicity risk assessments for pharmaceutical and biotech companies. EpiVax has been a pioneer in pre-clinical drug development for over 25 years, serving as a trusted scientific advisor to life sciences clients.

Why it matters

The acquisition of EpiVax aligns with SVHI's strategy of partnering with founders and management teams to build industry-leading healthcare businesses. EpiVax's expertise in immunogenicity risk assessment and computational tools are valuable assets that can help pharmaceutical and biotech companies improve their drug development processes and reduce R&D costs.

The details

Under the terms of the deal, SVHI will provide strategic guidance, capital, and access to its life sciences ecosystem to support EpiVax's continued growth and innovation. EpiVax will continue expanding its capabilities and services, with the coming launch of advanced computational tools, cell-based assay applications, and broader analytical consulting services.

  • EpiVax was founded in 1998.
  • The acquisition was announced on April 2, 2026.

The players

SV Health Investors

A private investment firm dedicated to investments in the healthcare and life sciences sector, with offices in Boston and London and over $2.0B in assets under management.

EpiVax, Inc.

A leading bioanalytical CRO specializing in immunogenicity risk assessments for pharmaceutical and biotech companies, headquartered in Providence, RI.

Annie De Groot, MD

The Founder of EpiVax.

A.J. Rossi

A Partner at SV Health Investors.

Rich-Henry Schabowsky, PhD, JD

The CEO of EpiVax.

Got photos? Submit your photos here. ›

What they’re saying

“This partnership marks an important next chapter for EpiVax and reflects SV Health Investors' confidence in our leadership team, differentiated capabilities, and scientific expertise.”

— Annie De Groot, MD, EpiVax Founder

“EpiVax has demonstrated exceptional growth – and we are excited to support the management team with strategic guidance, capital, and access to our life sciences ecosystem, while preserving the company's culture and customer-first approach.”

— A.J. Rossi, Partner at SV Health Investors

“The collaboration with SVHI strengthens EpiVax's position as a leader in immunogenicity risk assessment, accelerating our growth and science-driven innovation, while enhancing our ability to support global pharma and biotech partners in improving risk and resource management and more efficiently developing regulatory-ready strategies.”

— Rich-Henry Schabowsky, PhD, JD, EpiVax CEO

What’s next

EpiVax will continue expanding its capabilities and services, with the coming launch of advanced computational tools, cell-based assay applications, and broader analytical consulting services.

The takeaway

The acquisition of EpiVax by SV Health Investors strengthens EpiVax's position as a leader in immunogenicity risk assessment, providing the resources and expertise to support pharmaceutical and biotech companies in improving their drug development processes and reducing R&D costs.